Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free ESLAW Stock Alerts

Estrella Immunopharma (ESLAW) Competitors

Estrella Immunopharma logo
$0.06 0.00 (-3.52%)
As of 08/11/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

ESLAW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy Estrella Immunopharma stock or one of its competitors? Estrella Immunopharma's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Estrella Immunopharma compare to Alvotech?

Estrella Immunopharma (NASDAQ:ESLAW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/AN/AN/AN/A
Alvotech$559.42MN/AN/AN/AN/A

In the previous week, Alvotech had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for Alvotech and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.89 beat Alvotech's score of 0.93 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company Overall Sentiment
Estrella Immunopharma Very Positive
Alvotech Positive

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A N/A N/A
Alvotech N/A N/A N/A

Summary

Alvotech beats Estrella Immunopharma on 2 of the 3 factors compared between the two stocks.

How does Estrella Immunopharma compare to Apollomics?

Apollomics (NASDAQ:APLMW) and Estrella Immunopharma (NASDAQ:ESLAW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
Estrella ImmunopharmaN/AN/AN/AN/AN/A

In the previous week, Apollomics had 2 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for Apollomics and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.89 beat Apollomics' score of 0.29 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Apollomics Neutral
Estrella Immunopharma Very Positive

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Estrella Immunopharma N/A N/A N/A

Summary

Apollomics beats Estrella Immunopharma on 2 of the 3 factors compared between the two stocks.

How does Estrella Immunopharma compare to Aravive?

Estrella Immunopharma (NASDAQ:ESLAW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A N/A N/A
Aravive N/A N/A N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

In the previous week, Estrella Immunopharma had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for Aravive. Estrella Immunopharma's average media sentiment score of 1.89 beat Aravive's score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company Overall Sentiment
Estrella Immunopharma Very Positive
Aravive Neutral

Summary

Estrella Immunopharma and Aravive tied by winning 2 of the 4 factors compared between the two stocks.

How does Estrella Immunopharma compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and Estrella Immunopharma (NASDAQ:ESLAW) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
Estrella Immunopharma N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.61MN/AN/AN/AN/A
Estrella ImmunopharmaN/AN/AN/AN/AN/A

In the previous week, bioAffinity Technologies had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for bioAffinity Technologies and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.89 beat bioAffinity Technologies' score of 0.97 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company Overall Sentiment
bioAffinity Technologies Positive
Estrella Immunopharma Very Positive

Summary

bioAffinity Technologies beats Estrella Immunopharma on 2 of the 3 factors compared between the two stocks.

How does Estrella Immunopharma compare to BioVie?

Estrella Immunopharma (NASDAQ:ESLAW) and BioVie (NASDAQ:BIVIW) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

In the previous week, Estrella Immunopharma and Estrella Immunopharma both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 1.89 beat BioVie's score of 1.87 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company Overall Sentiment
Estrella Immunopharma Very Positive
BioVie Very Positive

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A N/A N/A
BioVie N/A N/A N/A

Summary

Estrella Immunopharma beats BioVie on 1 of the 1 factors compared between the two stocks.

Get Estrella Immunopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ESLAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESLAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ESLAW vs. The Competition

Export
MetricEstrella ImmunopharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.71B$7.08B$12.95B
Dividend YieldN/A3.76%2.57%10.34%
P/E RatioN/A10.37268.3925.05
Price / SalesN/A1,178.88559.4868.66
Price / CashN/A102.5472.2650.42
Price / BookN/A17.9713.226.18
Net IncomeN/A-$13.23M$3.44B$347.05M
7 Day PerformanceN/A3.24%2.07%1.24%
1 Month PerformanceN/A-1.13%-0.26%-0.65%
1 Year PerformanceN/A59.44%70.32%20.12%

Estrella Immunopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ESLAW
Estrella Immunopharma
N/A$0.06
-1.8%		N/A+65.1%$0.00N/AN/AN/A
ALVOW
Alvotech
N/A$0.15
flat		N/A-88.7%$0.00$559.42MN/A4
APLMW
Apollomics
N/A$0.01
-12.0%		N/A-29.0%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.09
+7.4%		N/A-37.5%$0.00$5.61MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ESLAW) was last updated on 8/12/2026 by MarketBeat.com Staff.
From Our Partners
This Junior Silver Explorer Is Closing In on Its Biggest Catalyst
A past-producing Nevada silver project holds a historical 36 million ounce silver-equivalent resource, plus mo...
Wall Street Logic | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Buffett's Final Warning: "The Dollar Is Going to Hell"
On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...
Decentralized Masters | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
The Pentagon is desperate
The Pentagon has admitted the US trails Russia and China in hypersonic weapons, and its research budget has ne...
Freedom Financial | Sponsoredtc pixel
Trump's Next Move Could Shrink Your Dollar
There's a plan in Washington being called the 'Mar-a-Lago Accord' - a deliberate strategy to weaken the U.S. d...
Priority Gold | Sponsoredtc pixel